Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Cardiotoxicity 8Osteosarcoma 5Recurrence 4Rhabdomyosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Neuroblastoma 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 3Leukemia 3Breast Neoplasms 3Sarcoma, Ewing 2Myelodysplastic Syndromes 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Ganglioneuroblastoma 2Dendritic Cell Sarcoma, Interdigitating 2Burkitt Lymphoma 2Blast Crisis 2Vomiting 1Unspecified Adult Solid Tumor, Protocol Specific 1Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Myeloid 1Rhabdoid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1

Interventions

Radiotherapy 10Doxorubicin 10Ifosfamide 9Vincristine 8Filgrastim 8Cyclophosphamide 8Dactinomycin 7Etoposide 5Carboplatin 4sargramostim 3Irinotecan 3Trabectedin 2Topotecan 2Radiotherapy, Conformal 2Neoadjuvant Therapy 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Epirubicin 2Chemotherapy, Adjuvant 2trioctyl phosphine oxide 1romidepsin 1pegfilgrastim 1indolepropanol phosphate 1etoposide phosphate 1cixutumumab 1brostallicin 1Watchful Waiting 1Vinorelbine 1Temozolomide 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Malignant mesenchymal tumor × Dexrazoxane × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡